Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jul 24;12(14):2810.
doi: 10.3390/foods12142810.

Mechanism of Anti-Diabetic Activity from Sweet Potato (Ipomoea batatas): A Systematic Review

Cokorda Istri Sri Arisanti  1   2 , I Made Agus Gelgel Wirasuta  2 , Ida Musfiroh  1 , Emmy Hainida Khairul Ikram  3   4   5 , Muchtaridi Muchtaridi  1   5
Affiliations
Review

Mechanism of Anti-Diabetic Activity from Sweet Potato (Ipomoea batatas): A Systematic Review

Cokorda Istri Sri Arisanti et al. Foods. .

Abstract

This study aims to provide an overview of the compounds found in sweet potato (Ipomoea batatas) that contribute to its anti-diabetic activity and the mechanisms by which they act. A comprehensive literature search was conducted using electronic databases, such as PubMed, Scopus, and Science Direct, with specific search terms and Boolean operators. A total of 269 articles were initially retrieved, but after applying inclusion and exclusion criteria only 28 articles were selected for further review. Among the findings, four varieties of sweet potato were identified as having potential anti-diabetic properties. Phenolic acids, flavonols, flavanones, and anthocyanidins are responsible for the anti-diabetic activity of sweet potatoes. The anti-diabetic mechanism of sweet potatoes was determined using a combination of components with multi-target actions. The results of these studies provide evidence that Ipomoea batatas is effective in the treatment of type 2 diabetes.

Keywords: Ipomoea batatas; anthocyanins; flavonoid; mechanism of action; phenolic acid; type 2 diabetes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart showing the literature search.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. International Diabetes Federation (IDF) Diabetes Atlas 10th Edition. [(accessed on 11 June 2023)]. Available online: https://diabetesatlas.org/atlas/tenth-edition/
    1. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S., Unwin N., Colagiuri S., Guariguata L., Motala A.A., Ogurtsova K., et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res. Clin. Pract. 2019;157:107843. doi: 10.1016/j.diabres.2019.107843. - DOI - PubMed
    1. European Medicines Agency Guideline on Clinical Investigation of Medicinal Products in the Treatment or Prevention of Diabetes Mellitus. 2012. [(accessed on 11 June 2023)]. Available online: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-cl....
    1. Garber A.J., Abrahamson M.J., Barzilay J.I., Blonde L., Bloomgarden Z.T., Bush M.A., Dagogo-Jack S., Davidson M.B., Einhorn D., Garvey W.T., et al. AACE comprehensive diabetes management algorithm 2013. Endocr. Pract. 2013;19:327–336. doi: 10.4158/EP13176.CSUPPL. - DOI - PubMed
    1. Inzucchi S.E. Oral antihyperglycemic therapy for type 2 diabetes: Scientific review. JAMA. 2002;287:360–372. doi: 10.1001/jama.287.3.360. - DOI - PubMed

LinkOut - more resources